Research in haemophilia B--approaching the request for high evidence levels in a rare disease.

about

Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.

P2860

Q40045534-899BD30C-587F-4340-BE46-9F6C1B026A17

P2860

Research in haemophilia B--approaching the request for high evidence levels in a rare disease.

Item

http://www.wikidata.org/entity/Q38286306

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Research in haemophilia B--app ...... ence levels in a rare disease.

@en

type

Item

label

Research in haemophilia B--app ...... ence levels in a rare disease.

@en

prefLabel

Research in haemophilia B--app ...... ence levels in a rare disease.

@en

P1476

Research in haemophilia B--app ...... ence levels in a rare disease.

@en

P2093

A Hilger

http://www.w3.org/2001/XMLSchema#string

D Schopohl

http://www.w3.org/2001/XMLSchema#string

M-E Behr Gross

http://www.w3.org/2001/XMLSchema#string

P Giangrande

http://www.w3.org/2001/XMLSchema#string

R Seitz

http://www.w3.org/2001/XMLSchema#string

W Schramm

http://www.w3.org/2001/XMLSchema#string

P2860

Lack of seasonal variation in bleeding and patient-assessed pain patterns in patients with haemophilia B receiving on-demand therapy.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B

Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.

Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008.

Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.

Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.

A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.

Joint WFH-ISTH session: issues in clinical trial design.

Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.

Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.

P304

4-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.12603

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Flora Peyvandi

Karin Berger

P577

2014-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269418946

http://www.w3.org/2001/XMLSchema#string

P698

25495927

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

hemophilia B

rare disease

Research in haemophilia B--approaching the request for high evidence levels in a rare disease.

about

P2860

P2860

Research in haemophilia B--approaching the request for high evidence levels in a rare disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921